| Author (References) | Age (year) gender | Time after the diagnosis of Sjögren’s syndrome | Articular Symptomatology | Extra articular symptomatology | Immunology | AA Amyloidosis (Systemic/Localized) | Lymphomatous degeneration | Treatment | Outcome after treatment |
| Costa et al. [3] | 79 F | 22 days | NA | Rapidly progressive renal failure asthenia, anorexia and generalized oedema | ANA+ (1:80) Anti-SSA+ (>200 UI/ml) Anti-SSB+ (40 U/ml) RF+ (88.6 IU/ml) | Renal | No | Corticosteroids haemodialysis | Death |
| Motegi et al. [4] | 58 F | 8 years | NA | Ocular, buccal dryness | NA | Pulmonary | NA | NA | NA |
| Wong et al. [5] | 29 F | At the time of diagnosis | NA | NA | NA | Pulmonary | No | NA | NA |
| Parambil et al. [6] | NA | NA | NA | Dyspnea | NA | Pulmonary | No | Corticosteroids Immunosuppression | NA |
| Ooms et al. [9] | 53 M | 18 years | NA | Acute renal failure and nephrotic syndrome | NA | Renal | No | Corticosteroids | Favorable |
| Katsikas et al. [7] | 62 F | NA | Polyarthritis | Mild mixed sensory-motor axonal polyneuropathy | ANA+ (1:640) Anti-SSA+ Anti-SSB+ RF+ (3600 IU/ml) | Cutaneous | No | Corticosteroids hydroxychloroquine | Favorable |
| Case 1 | 54 F | 1 year | Mechanical arthralgia | Ocular, buccal and cutaneous dryness Myalgia, generalized fatigue, skin hyperpigmentation and paroxysmal parotidomegaly | ANA+ Anti-SSA+ (200 IU/ml) Anti-SSB- | Accessory Salivary Glands | No | Rituximab | Favorable |
| Case 2 | 55 F | 6 years | Inflammatory arthralgia | Renal failure | ANA+ Anti-SSA+ Anti-SSB-RF+ (252 IU/ml) | Accessory Salivary Glands Renal (inconclusive biopsy) | No | Rituximab Corticosteroids | Stationary |